Welcome to our dedicated page for FibroBiologics news (Ticker: FBLG), a resource for investors and traders seeking the latest updates and insights on FibroBiologics stock.
FibroBiologics, Inc. (Nasdaq: FBLG) is a clinical-stage biotechnology company based in Houston, specializing in the development and commercialization of fibroblast-based therapies for treating a range of chronic diseases with unmet medical needs. These include degenerative disc disease, multiple sclerosis, wound healing, certain cancers, and potential life-extending applications like thymic and splenic involution reversal.
Core Business and Focus: The company leverages human dermal fibroblasts (HDFs) to develop innovative treatments aimed at reducing inflammation and promoting tissue regeneration. Their technology is backed by over 150 issued and pending patents across multiple clinical pathways.
Recent Achievements: FibroBiologics recently presented promising preclinical data at the 2024 Keystone Symposia for Systemic Autoimmune and Autoinflammatory Diseases. The study demonstrated the efficacy of HDF spheroids in treating psoriasis in a mouse model, significantly reducing skin lesion severity and autoimmune inflammation.
Current Projects: Ongoing research includes the development of fibroblast-based pancreatic beta cell spheroids to secrete insulin in vitro, which could become a groundbreaking treatment for insulin-dependent diabetes. Additionally, the company is exploring the use of HDF spheroids for accelerating wound healing in diabetic patients.
Financial Condition: FibroBiologics has recently filed its Annual Report on Form 10-K for the year ended December 31, 2023, showcasing strong financial health and strategic advancements in their clinical programs.
Partnerships: To expedite the clinical translation of their fibroblast-based therapies, FibroBiologics is collaborating with Charles River to optimize cell manufacturing processes and ensure high-quality drug product development for clinical trials.
FibroBiologics represents the next generation of medical advancement in cell therapy, continually pushing the boundaries of regenerative medicine to bring innovative treatments to patients worldwide.
FibroBiologics (Nasdaq: FBLG) has filed a patent application for treating splenomegaly using cell-based therapeutics. The application focuses on treating enlarged spleen conditions, which commonly occur in autoimmune disorders, chronic infections, and as a side effect of chemotherapy. The company's approach utilizes fibroblast-based therapies to address immune dysregulation, potentially offering a new treatment method for managing immune system overload and spleen enlargement. This development adds to FibroBiologics' portfolio of 160+ issued and pending patents in chronic disease therapeutics.
FibroBiologics (Nasdaq: FBLG) has filed a patent application for methods using fibroblasts and Tissue Factor-expressing cells to prevent IBMIR-mediated blood clotting in cell therapy treatments. The technology aims to address a major challenge in cell therapy by reducing inflammatory and coagulative responses that can compromise treatment effectiveness and safety. The approach focuses on minimizing complications such as complement activation, immune cell infiltration, and platelet adhesion during intravascular, subcutaneous, and intraperitoneal cell administration. This development could potentially improve the safety and efficacy of cell-based treatments by reducing adverse events and rejection by the body's immune system.
FibroBiologics (NASDAQ: FBLG) reported Q3 2024 financial results and corporate updates. The company plans to initiate a Phase 1/2 clinical trial for its CYWC628 product to treat diabetic foot ulcers in Q2 2025. For the nine months ended September 30, 2024, R&D expenses increased to $3.1M from $1.6M, and G&A expenses rose to $6.9M from $4.8M year-over-year. Net loss widened to $8.1M compared to $6.8M in the same period of 2023. Cash position stood at $7.8M as of September 30, 2024. The company expanded its IP portfolio with multiple patent issuances and joined the Russell 2000® Index.
FibroBiologics (Nasdaq: FBLG) reported promising results from its artificial thymus organoid program. The technology demonstrated that fibroblasts and thymus-derived cell organoids can maintain functionality for over 50 days after transplantation, showing vascularization and generating diverse mature T cells in animal models. The organoids produced fully mature T cells with various differentiation capabilities, including CD4, CD8, T-regulatory, and gamma delta T cells. The artificial thymus also generates T cells with diverse TCR-beta chains for broad antigen recognition, potentially supporting immune function in patients with immune dysregulation or post-chemotherapy conditions.
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotechnology company with 160+ patents, announced upcoming presentations at two major conferences. The company will present at the 2024 ThinkEquity Conference in New York on October 30, 2024, at 10:30 a.m. ET, and at BIO-Europe 2024 in Stockholm on November 5, 2024, at 1:30 p.m. CET.
FibroBiologics specializes in developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials. Their patent portfolio covers various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.
FibroBiologics (Nasdaq: FBLG) and Charles River Laboratories have established a master services agreement to develop and manufacture FibroBiologics' therapeutic master cell bank, working cell bank, and fibroblast-based spheroids product, CYWC628, for a diabetic foot ulcer (DFU) clinical trial planned for 2025. The collaboration aims to leverage Charles River's expertise in cell and gene therapy manufacturing to support FibroBiologics' innovative fibroblast-based therapies for chronic diseases.
Key points:
- Technology transfer and feasibility studies have been successfully completed
- Charles River will serve as the contract development and manufacturing organization (CDMO) for FibroBiologics' clinical trial drug products
- The partnership is expected to accelerate progress in delivering fibroblast-based treatments to patients
- FibroBiologics is investigating fibroblasts and fibroblast-derived materials for multiple indications, including wound healing, multiple sclerosis, and cancer
FibroBiologics (Nasdaq: FBLG) has been granted a patent by the European Patent Office for a novel cancer treatment method using modified fibroblasts to deliver anti-cancer agents. The patent (Number 19795975.2) covers methods and compositions for enhancing fibroblasts' ability to target cancerous tissues and deliver tumor-inhibiting agents directly to cancer cells.
This innovative approach aims to improve the effectiveness of cancer treatments by leveraging fibroblasts' natural ability to penetrate tumor tissues and modulate immune responses. The technology could potentially address challenges faced by traditional therapies, such as tumor penetration, and may offer new possibilities for treating primary, metastatic, and treatment-resistant tumors.
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotechnology company, announced its participation in the 2024 Maxim Healthcare Virtual Summit. CEO Pete O'Heeron will engage in a fireside chat on October 16, 2024, at 10:00 a.m. ET.
FibroBiologics specializes in developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials. The company boasts over 160 issued and pending patents across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.
Based in Houston, FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, interested parties can visit the company's website or contact them directly via email.
FibroBiologics (Nasdaq: FBLG) announced that Chief Scientific Officer, Hamid Khoja, Ph.D., will present at the 2024 Cell & Gene Meeting on the Mesa Conference in Phoenix, Arizona, on October 7, 2024. The presentation will focus on updates regarding the company's pre-clinical IND-enabling studies in chronic wound healing and psoriasis, as they prepare for a phase I/II diabetic foot ulcer (DFU) clinical trial with their CYWC628 topically administered fibroblast spheroid product candidate.
Dr. Khoja emphasized the company's approach of leveraging the regenerative potential of fibroblasts for tissue repair and immune modulation. FibroBiologics aims to create innovative cell-based approaches for treating chronic diseases. The presentation is scheduled for 5:45 p.m. MST in the FLW Ballroom F.
FibroBiologics (Nasdaq: FBLG) has engaged Southern Star Research as its CRO in Australia to prepare for a Phase 1/2 clinical trial of CYWC628, a treatment for diabetic foot ulcers. This partnership aims to leverage Australia's high-quality clinical trial infrastructure and R&D incentives. CYWC628 is an allogeneic fibroblast cell-based therapy designed to promote wound healing, particularly for difficult-to-treat diabetic foot ulcers.
CEO Pete O'Heeron stated that this engagement is important for establishing FibroBiologics' clinical trial infrastructure in Australia. The company, with 160+ patents issued and pending, focuses on developing therapeutics for chronic diseases using fibroblasts and fibroblast-derived materials.
FAQ
What is the current stock price of FibroBiologics (FBLG)?
What is the market cap of FibroBiologics (FBLG)?
What does FibroBiologics, Inc. specialize in?
What are fibroblasts and how are they used?
What recent achievements has FibroBiologics made?
What are the current projects of FibroBiologics?
What is the financial condition of FibroBiologics?
Who are FibroBiologics' key partners?
What diseases is FibroBiologics targeting with their therapies?
How many patents does FibroBiologics hold?
Where is FibroBiologics based?
How can I learn more about FibroBiologics?
